evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

404 questions · 409 findings · 122 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 77 · 18.8%GRADE not reported 31 · 7.6%Very low 142 · 34.7%Low 83 · 20.3%Moderate 63 · 15.4%High 13 · 3.2%

Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis vs on‐demand therapy

Serious adverse events · people without inhibitors

Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma

All serious adverse events · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use

It is very uncertain whether summary of findings table ‐ Prothrombin complex concentrates changes all serious adverse events compared with fresh frozen plasma (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control

All serious adverse events · adults with acute spontaneous intracerebral haemorrhage

It is very uncertain whether summary of findings table ‐ Recombinant activated factor VII changes all serious adverse events compared with placebo/open control (very low certainty).

1 finding from 1 review

Lifestyle interventions vs placebo or usual care

Adverse events – musculoskeletal · weight reduction in obesity to improve survival in women with endometrial cancer

It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes adverse events – musculoskeletal compared with usual care compared to placebo (very low certainty).

1 finding from 1 review

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings 1: PLD with chemotherapy showed no clear difference in overall severe adverse events (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).

1 finding from 1 review